
Navamedic ASA – OSE:NAVA.OL
Navamedic ASA stock price today
Navamedic ASA stock price monthly change
Navamedic ASA stock price quarterly change
Navamedic ASA stock price yearly change
Navamedic ASA key metrics
Market Cap | 671.88M |
Enterprise value | 687.86M |
P/E | 84.26 |
EV/Sales | 2.58 |
EV/EBITDA | 35.83 |
Price/Sales | 2.47 |
Price/Book | 3.54 |
PEG ratio | 0.83 |
EPS | -0.67 |
Revenue | 511.15M |
EBITDA | 25.24M |
Income | -11.44M |
Revenue Q/Q | -0.75% |
Revenue Y/Y | 15.92% |
Profit margin | 2.42% |
Oper. margin | 8.24% |
Gross margin | 40.02% |
EBIT margin | 8.24% |
EBITDA margin | 4.94% |
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeNavamedic ASA stock price history
Navamedic ASA stock forecast
Navamedic ASA financial statements
Jun 2023 | 123.96M | -15.77M | -12.72% |
---|---|---|---|
Sep 2023 | 140.99M | 6.77M | 4.8% |
Dec 2023 | 125.31M | -861K | -0.69% |
Mar 2024 | 120.87M | -1.58M | -1.31% |
2025 | 673.79M | 59.35M | 8.81% |
---|---|---|---|
2026 | 791M | 68M | 8.6% |
2027 | 880M | 87.18M | 9.91% |
2028 | 955M | 100.74M | 10.55% |
Analysts Price target
Financials & Ratios estimates
2023-11-01 | 0.31 | 0.39 |
---|
Jun 2023 | 455247000 | 243.80M | 53.55% |
---|---|---|---|
Sep 2023 | 484851000 | 266.58M | 54.98% |
Dec 2023 | 524304999 | 301.91M | 57.58% |
Mar 2024 | 536908000 | 310.75M | 57.88% |
Jun 2023 | -988K | -89.10M | 69.73M |
---|---|---|---|
Sep 2023 | 23.05M | -9.90M | -158K |
Dec 2023 | -27.24M | -5.94M | 22.27M |
Mar 2024 | -5.56M | -185K | -1.91M |
Navamedic ASA alternative data
Aug 2023 | 35 |
---|---|
Sep 2023 | 45 |
Oct 2023 | 45 |
Nov 2023 | 45 |
Dec 2023 | 34 |
Jan 2024 | 34 |
Feb 2024 | 34 |
Mar 2024 | 34 |
Apr 2024 | 34 |
May 2024 | 34 |
Jun 2024 | 45 |
Jul 2024 | 45 |
Navamedic ASA other data
Insider | Compensation |
---|---|
Ms. Kathrine E. Gamborg Andreassen (1966) Chief Executive Officer | $4,210,000 |
-
What's the price of Navamedic ASA stock today?
One share of Navamedic ASA stock can currently be purchased for approximately $32.5.
-
When is Navamedic ASA's next earnings date?
Unfortunately, Navamedic ASA's (NAVA.OL) next earnings date is currently unknown.
-
Does Navamedic ASA pay dividends?
No, Navamedic ASA does not pay dividends.
-
How much money does Navamedic ASA make?
Navamedic ASA has a market capitalization of 671.88M and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 33.98% to 512M US dollars. Navamedic ASA earned 3.3M US dollars in net income (profit) last year or $0.39 on an earnings per share basis.
-
What is Navamedic ASA's stock symbol?
Navamedic ASA is traded on the OSE under the ticker symbol "NAVA.OL".
-
What is Navamedic ASA's primary industry?
Company operates in the Healthcare sector and Medical Distribution industry.
-
How do i buy shares of Navamedic ASA?
Shares of Navamedic ASA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Navamedic ASA's key executives?
Navamedic ASA's management team includes the following people:
- Ms. Kathrine E. Gamborg Andreassen Chief Executive Officer(age: 59, pay: $4,210,000)
-
How many employees does Navamedic ASA have?
As Jul 2024, Navamedic ASA employs 45 workers, which is 32% more then previous quarter.
-
When Navamedic ASA went public?
Navamedic ASA is publicly traded company for more then 19 years since IPO on 31 Mar 2006.
-
What is Navamedic ASA's official website?
The official website for Navamedic ASA is navamedic.com.
-
How can i contact Navamedic ASA?
Navamedic ASA can be reached via phone at +47 67 11 25 40.
Navamedic ASA company profile:

Navamedic ASA
navamedic.comOSE
35
Medical Distribution
Healthcare
Navamedic ASA, a pharmaceutical company, develops, produces, markets, and sells pharmaceuticals and related products in Northern Europe. The company's product portfolio includes prescription and non-prescription pharmaceuticals, as well as medical nutrition products, medical devices, food supplements, and cosmetics. It offers medical nutrition products for various therapeutic areas, including phenylketonuria, homocystinuria, maple syrup urine disease, tyrosinemia, methylmalonic acidemia/propionic acidemia, glutaric aciduria, isovaleric acidemia, and urea cycle disorders, as well as products for glycogen storage diseases and renal diseases, fat metabolism, malnutrition, and ketogenic diet. In addition, the company provides consumer health products consisting of non-prescription drugs and health care products for pain relief, cough and cold, gastro, women's health, and others primarily through pharmacies and drugstores; specialty pharmaceutical products in various therapeutic areas comprising dermatology, wound care, women's health, urology, and obesity; and branded generics, including cardiology products and antibiotics. It sells, markets, and distributes its products to hospitals, patients, and pharmacies. The company was formerly known as Glucomed AS and changed its name to Navamedic ASA in 2004. Navamedic ASA was incorporated in 2002 and is headquartered in Oslo, Norway.
Oslo, 0255
:
ISIN: NO0010205966
: